DoseGear research brief
Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.
DG Peptide Protocols
EmergingCognitiveLongevity
PE-22-28
Mini-Spadin
TREK-1 Channel Blocker | Shortened Spadin Analog
Research overview
Mechanism of action
Selectively blocks TREK-1 potassium channels (IC50: 0. 12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Shortened spadin-related peptide.
What it is researched for
Preclinical antidepressant and neuroplasticity research through TREK-1 potassium-channel inhibition.
Research observation window
The source reports approximately 23-hour experimental activity; a validated human mood-response window is not reported.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Antidepressant Effect | 50-200mcg | Once daily | SubQ |
| Neurogenesis Support | 100-200mcg | Once daily | SubQ |
Reference cycle
4-8 weeks
Reference storage
Refrigerate at 2-8°C, use within 4-6 weeks
Safety context
Reported side effects
- No effects on TREK-2, TRAAK, TASK-1 channels observed
- No cardiac dysfunction or seizures in preclinical studies
Contraindications & cautions
- Pregnancy and breastfeeding
- Concurrent MAOI use
Scientific references
- 01
Shortened Spadin Analogs Display Better TREK-1 Inhibition
Scientific citationShortened Spadin Analogs Display Better TREK-1 Inhibition. (2017). - 02
Spadin: A Sortilin-Derived Peptide Targeting TREK-1 Channels
Scientific citationSpadin: A Sortilin-Derived Peptide Targeting TREK-1 Channels. (2010). - 03
TREK-1 Deletion Results in Depression-Resistant Phenotype
Scientific citationTREK-1 Deletion Results in Depression-Resistant Phenotype. (2006).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.